$186.92 -$2.28 (-1.2%)

04:00 PM EST on 12/06/19

BeiGene (NASDAQ:BGNE)

CAPS Rating: 5 out of 5

Current Price $186.92 Mkt Cap $11.4B
Open $190.00 P/E Ratio 0.00
Prev. Close $189.20 Div. (Yield) $0.00 (0.0%)
Daily Range $185.32 - $190.27 Volume 506,606
52-Wk Range $108.00 - $210.35 Avg. Daily Vol. 392,802

Caps

How do you think NASDAQ:BGNE will perform against the market?

Add Stock to CAPS Watchlist

All Players

35 Outperform
0 Underperform
 

All-Star Players

14 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:BGNE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFInnovator (90.80)
Submitted July 09, 2018

BeiGene is a biotech company focused on becoming “the Genetech of China.” Its approach involves developing cancer immunotherapy drugs that are personalized for patients who can be characterized by their particular tumor subgroup.Its research platform… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:BGNE VS S&P 500 (SPY)

NASDAQ:BGNE Summary

Fools bullish on NASDAQ:BGNE are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about BGNE.

Recs

0
Member Avatar Bigsef77 (69.72) Submitted: 1/15/2019 3:16:53 PM : Outperform Start Price: $168.98 NASDAQ:BGNE Score: +0.52

BeiGene drug gets 'breakthrough therapy' designation from FDA
[MarketWatch]
Wallace Witkowski
,MarketWatch•January 14, 2019

U.S. shares of BeiGene Ltd. rose in the extended session Monday after the biotech drug developer said the Food and Drug Administration will expedite the regulatory process for one of its drugs. BeiGene ADRs rose 4% after hours, following a 4.6% decline to close at $137.55 Monday. The company said the FDA gave a "Breakthrough Therapy" designation to its mantle cell lymphoma treatment, meaning the experimental drug zanubrutinib will get expedited review and guidance from the agency.

Recs

0
Member Avatar freecapital (76.88) Submitted: 9/6/2018 6:52:27 AM : Outperform Start Price: $168.41 NASDAQ:BGNE Score: +2.10

innovator

Recs

0
Member Avatar danieljosefo (48.11) Submitted: 1/2/2018 1:40:28 PM : Outperform Start Price: $100.13 NASDAQ:BGNE Score: +69.33

This company's value is as a gate keeper for a huge pharmaceutical market in China. Its deal with Celgene may only be the first of several with other companies. And its own organic growth and inhouse development potential provide significant additional upside.

Leaderboard

Find the members with the highest scoring picks in BGNE.

Score Leader

portefeuille

portefeuille (98.38) Score: +546.89

The Score Leader is the player with the highest score across all their picks in BGNE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille 98.38 2/10/2016 Outperform 5Y $26.13 +615.35% +68.46% +546.89 0 Comment
jeepdrew222 66.16 9/8/2016 Outperform 5Y $29.68 +529.78% +44.02% +485.77 0 Comment
portefeuille3 97.13 9/28/2016 Outperform 5Y $30.81 +506.69% +46.12% +460.56 0 Comment
SeriousK 28.85 11/29/2016 Outperform 5Y $31.07 +501.61% +42.78% +458.83 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 98.61 5/23/2017 Outperform 5Y $36.87 +406.97% +31.21% +375.76 0 Comment
portefeuille2 99.12 9/1/2017 Outperform 5Y $69.45 +169.14% +27.00% +142.15 0 Comment
sublimeinvestor 29.98 8/8/2017 Outperform 5Y $77.30 +141.81% +26.78% +115.03 0 Comment
Plasmidologist 30.88 8/8/2017 Outperform 5Y $77.49 +141.22% +26.77% +114.45 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. danieljosefo 48.11 1/2/2018 Outperform 3Y $100.13 +86.68% +17.35% +69.33 1 Comment
drnetops1958 < 20 5/9/2019 Outperform 5Y $122.27 +52.87% +10.38% +42.49 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BGNE.